Prediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome Signatures

Ulcerative Colitis Clinical Trial

— PREDUCTOME  

Official title:

Prediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome Signatures

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05579483
• Other study ID #: NL79442.091.22
• Secondary ID: NL79442.091.22
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2023
• Est. completion date: October 2025

Study information

• Verified date: April 2023
• Source: Wageningen University
• Contact: Erwin G Zoetendal, PhD
• Phone: +31 (0)317- 483111
• Email: erwin.zoetendal[@]wur.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A double-blind randomized placebo-controlled parallel trial with two intervention arms and two placebo arms and a period of eight intervention weeks to validate the prediction that prebiotics could induce a higher response in mild UC patients with certain fecal microbiome signatures.

Description:

Rationale: Ulcerative colitis (UC) patients respond differently to treatments/interventions (e.g. diet/fecal microbiota transplantation), but the reason for this individual specificity remains unknown. The investigators hypothesize that the baseline fecal microbiota composition determines the efficacy of a treatment/intervention, and potential responders, i.e. patients showing symptoms improvement after treatment, can be predicted based on fecal microbiota composition.

Objective: The primary objective is to validate the prediction that prebiotics intervention boosts butyrate production and thereby induces a higher response (lower mean Patient Simple Clinical Colitis Activity Index (P-SCCAI) score) in mild UC patients with low intestinal Bacteroidetes levels (predicted responders), but not in those with high intestinal Bacteroidetes levels (predicted non-responders) at T = 8 weeks. The secondary objectives are to study the effects of prebiotics intervention on disease activity over time (T = 0, 4, 8, 12 and 60 weeks), mucosal inflammation, gastro-intestinal (GI) complaints, stool consistency, stool frequency, fecal microbiota composition, fecal short-chain fatty acids concentrations, quality of life, number of participants with increased or decreased medication use, and incidence of adverse events in mild UC patients.

Study design: This study is a four-arm double-blind randomized placebo-controlled parallel trial. It consists of a screening stage in which mild UC patients will be assigned to be predicted responders or predicted non-responders based on fecal Bacteroidetes levels. Afterwards the predicted responders and non-responders will be assigned to either the prebiotics group (arm 1 and 3) or placebo group (arm 2 and 4).

Study population: Adult subjects aged 18-65 years and body mass index 18-30 kg/m2 with mild UC defined by P-SCCAI (3-5 points in a 19-point scale), with at least one relapse in the last two years.

Intervention: An 8-week intervention period with four parallel arms: 1) predicted responders with prebiotics treatment (acacia gum, partially hydrolyzed guar gum, and resistant starch), 2) predicted responders with placebo (maltodextrin and corn starch), 3) predicted non-responders with prebiotics treatment, 4) predicted non-responders with placebo, during which the study participants consume the respective supplement (3 grams, twice daily).

Main study parameters/endpoints: The main parameter is the response (mean P-SCCAI score) between arms at T = 8 weeks. The secondary parameters are the disease activity over time at T = 0, 4, 8, 12, and 60 weeks, mucosal inflammation (fecal calprotectin), gastro-intestinal (GI) complaints, stool consistency, stool frequency, fecal microbiota composition, fecal short-chain fatty acids concentrations, health-related quality of life, number of participants with increased or decreased medication use, and incidence of adverse events.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: October 2025
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male and female subjects aged 18 to 65 years

2. Body Mass Index (BMI) between 18 and 30 kg/m2 (self-reported)

3. Ulcerative Colitis confirmed via previous endoscopy and histology

4. Mild active UC as defined by P-SCCAI score of 3 to 5 (range 0 to 19)

5. Frequent relapse (at least one exacerbation in the last two years)

6. No known allergy to any components of the study product (self-reported)

7. Signed informed consent

8. Stable UC medication defined as no switch to other medication or no dose change

9. Mobile phone on which apps (used for questionnaires) can be downloaded (iOS version 9 and newer, Android version 4.4 and newer. Phones manufactured after 2013 are usually suitable)

10. Stable dietary pattern during the study

Exclusion Criteria:

1. Any other underlying disease of the GI-tract or previous bowel surgery, except cholecystectomy and appendectomy

2. Pregnancy or intending to become pregnant during the study

3. Use of medication that can interfere with the study outcomes, as judged by the medical supervisor

4. The need for antibiotic use during the intervention period

5. Systemic antibiotics and proton pump inhibitors (except for omeprazole and pantoprazole with dosage <20 mg), prebiotic supplements, probiotic supplements four weeks prior to study start

6. Currently participating in another intervention study

7. Acquaintances of anyone in the research team

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Dietary Supplement:
• Prebiotics
The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
• Placebo
The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.

Locations

Country	Name	City	State
Netherlands	Wageningen University	Wageningen	Gelderland

Sponsors (3)

Lead Sponsor	Collaborator
Wageningen University	China Scholarship Council, Winclove Probiotics B.V.

Country where clinical trial is conducted

Netherlands, 

References & Publications (2)

Fassarella M, Blaak EE, Penders J, Nauta A, Smidt H, Zoetendal EG. Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health. Gut. 2021 Mar;70(3):595-605. doi: 10.1136/gutjnl-2020-321747. Epub 2020 Oct 13. — View Citation

Liu Z, de Vries B, Gerritsen J, Smidt H, Zoetendal EG. Microbiome-based stratification to guide dietary interventions to improve human health. Nutr Res. 2020 Oct;82:1-10. doi: 10.1016/j.nutres.2020.07.004. Epub 2020 Jul 21. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Habitual dietary intake	Habitual dietary intake including energy, nutrient, and fiber intake of the last month will be assessed by a validated food frequency questionnaire (FFQ) via FFQ-tool, a web-based interface tool.	FFQ will be taken at T= 0 (baseline).
Other	Participants demographics and characteristics	General information (e.g., sex, age, BMI, disease duration, age at diagnosis, smoking habit, UC location, type of treatment) will be collected	This information will be collected at T= 0 (baseline).
Primary	Response between arms at T = 8 weeks	Within each arm, response will be determined by the mean Patient Simple Clinical Colitis Activity Index (P-SCAAI) score on a nineteen-point scale (from "0: no symptoms" to "19: severest symptom"). It refers to disease activity during the previous week, with higher scores representing worse disease symptoms.	Response at the end the intervention (T= 8 weeks)
Secondary	Disease activity over time (T= 0, 4, 8, 12, and 60 weeks)	Disease activity will be determined by the Patient Simple Clinical Colitis Activity Index (P-SCAAI) score on a nineteen-point scale (from "0: no symptoms" to "19: severest symptom"). With P-SCCAI score <= 2 being regarded as clinical remission, and a decrease in the P-SCCAI score by more than two points from baseline being regarded as clinical response. Comparisons will be made between groups as well as within subjects over time.	Disease activity during and after the intervention (at T= 0, 4, 8, 12, and 60 weeks)
Secondary	Mucosal inflammation	Mucosal inflammation will be determined by the fecal calprotectin level, which is a biomarker of inflammation and disease activity.	Change during and after the intervention (at T= 0, 8, 12, and 60 weeks)
Secondary	GI complaints	The GI complaints will be assessed by the (gastrointestinal symptom rating scale) GSRS questionnaire, which has a seven-point graded scale where 1 represents the absence of troublesome symptoms and 7 represents very troublesome symptoms.	Change during the intervention (at T= 0, 4, and 8 weeks)
Secondary	Stool consistency	Stool consistency will be measured using the Bristol Stool Form Scale (7-point scale from 1=hard to 7=diarrhea) on a daily basis for 7 days	Change during the intervention (at T= 0, 4, and 8 weeks)
Secondary	Stool frequency	Stool frequency will be measured by counting number of defecation on a daily basis for 7 days.	Change during the intervention (at T= 0, 4, and 8 weeks)]
Secondary	Fecal microbiota composition	Fecal microbiota composition will be determined by 16S rRNA gene sequencing.	Change during and after the intervention (at T= 0, 8, 12, and 60 weeks)
Secondary	Fecal short-chain fatty acids concentrations	Fecal short-chain fatty acids concentrations will be determined by HPLC.	Change during and after the intervention (at T= 0, 8, 12, and 60 weeks)
Secondary	Health-related quality of life	Health-related quality of life will be assessed by short inflammatory bowel disease questionnaire (SIBDQ) with a seven-point graded scale where 1 represents very troublesome symptoms and 7 represents the absence of troublesome symptoms.	Change during the intervention (at T= 0, 4, and 8 weeks)
Secondary	Number of participants with increased or decreased medication use	It consists of the current medication use (e.g., aminosalicylates, corticosteroids, immunosuppressive agents, antimicrobial agents, and inhibitors of tumour necrosis factor-alpha (TNF- a)) with a downgrade meaning improvement and an upgrade meaning worsening of UC.	Change during and after the intervention (at T= 0, 4, 8, 12, and 60 weeks)
Secondary	Incidence of adverse events	Incidence of adverse events will be monitored by patient record and diary, these include all relapse-relevant information, including the need for systemic steroids, hospitalization, and surgery.	Change during the intervention (at T= 0, 4, and 8 weeks)